Pyrukynd (mitapivat) is an oral pyruvate kinase activator indicated for the treatment of hemolytic anemia in adults with pyruvate kinase (PK) deficiency.
Pyrukynd (Mitapivat) for Pyruvate Kinase Deficiency
read more
Horizon Scanning
It is a challenge for health plans and clinicians to know what emerging technologies are in the preapproval phase and what their clinical, financial, and risk impacts might be. This is where we come in.The Hayes Horizon Scanning Solution identifies innovative and potentially disruptive health technologies that are in various stages of the regulatory approval process. Our Research Analysts continually investigate new technologies that are on the horizon or in the early stages of clinical investigation, as well as the testing of existing technologies that may be seeking approval for new clinical applications. Hayes Horizon Scanning helps you track emerging technologies before you need to make decisions. Accessed through the Hayes Knowledge Center, Hayes Horizon Scanning addresses the following fundamental questions to help our clients forecast emerging technologies:
- Is this emerging technology new or replacing an existing technology?
- Where is this technology in the FDA regulatory process?
- When will this technology be commercially available in the market?
- What is the projected use, cost, and financial impact of this technology?
Teplizumab for the Delay of Type 1 Diabetes
Teplizumab is an intravenously administered anti-CD3 monoclonal antibody in development for the delay of clinical type 1 diabetes (T1D) in at-risk individuals.
Vutrisiran for Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis
Vutrisiran is an injectable RNA interference (RNAi) therapeutic agent under investigation for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.
CureSight for Amblyopia in Children
CureSight is a prescription digital therapeutic that combines eye-tracking sensors, image processing algorithms, and real-time remote monitoring under investigation for treatment of amblyopia in children aged 4 to 9 years.
RBX2660 for Fecal Microbiota Transplantation
RBX2660 is a microbiota-based investigational product for fecal microbiota transplantation proposed to treat recurrent Clostridoides difficile infection. It is derived from fresh stool from multiple donors; both donors and stool samples are methodically screened. Pooled stool samples are commercially prepared under good manufacturing processes. …
Luminopia One for Amblyopia in Children
The Luminopia One is a software-only digital therapeutic used with commercially available head-mounted displays intended for home use for improvement in visual acuity in amblyopia patients aged 4-7 years associated with anisometropia and/or with mild strabismus, having received treatment instructions (frequency and duration) as prescribed by a trained eye care professional.
Darvadstrocel for Perianal Fistula in Crohn Disease
Darvadstrocel is an injectable allogeneic, expanded, adipose-derived mesenchymal stem cell product. It is proposed as an adjunct to standard medical care for treatment-refractory complex perianal fistula in adults with Crohn disease. Darvadstrocel is in phase III clinical trial development for a future regulatory filing with the FDA. It is currently approved under the brand n…
Melphalan Hepatic Delivery System (Hepzato Kit) for Liver-Dominant Metastatic Ocular Melanoma
The Melphalan Hepatic Delivery System (M-HDS; proposed U.S. name, Hepzato Kit) is a catheter-based drug delivery and chemofiltration kit for intra-arterial administration of melphalan chemotherapy directly to the liver followed by extracorporeal filtration of hepatic venous blood to reduce melphalan concentration before returning blood to systemic circulation. It is used to p…
eCoin Peripheral Neurostimulator System for Urgency Urinary Incontinence
The eCoin Peripheral Neurostimulator is a leadless implantable tibial nerve neurostimulator indicated to treat urgency urinary incontinence (UUI) in patients intolerant to or having inadequate response to other more conservative treatments or who have undergone a successful trial of percutaneous tibial nerve stimulation (TNS).
Fexapotide Triflutate for Benign Prostatic Hyperplasia
Fexapotide triflutate is an investigational injectable apoptotic agent proposed for the treatment of benign prostatic hypertrophy (BPH).